A breakdown of the latest mutual funds holding Matinas Biopharma Holdings Inc (MTNB)

In yesterday’s Wall Street session, Matinas Biopharma Holdings Inc (AMEX:MTNB) shares traded at $0.28, down -13.78% from the previous session.

As of this writing, 2 analysts cover Matinas Biopharma Holdings Inc (AMEX:MTNB). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $3.00 and a low of $0.30, we find $1.65. Given the previous closing price of $0.32, this indicates a potential upside of 415.62 percent. MTNB stock price is now 43.29% away from the 50-day moving average and -25.53% away from the 200-day moving average. The market capitalization of the company currently stands at $59.94M.

There are 0 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $1.65 as their price target over the next twelve months.

A total of 2.92% of the company’s stock is owned by insiders.

Wednesday morning saw Matinas Biopharma Holdings Inc (AMEX: MTNB) opened at $0.2996. During the past 12 months, Matinas Biopharma Holdings Inc has had a low of $0.11 and a high of $0.89. As of last week, the company has a debt-to-equity ratio of 0.14, a current ratio of 9.27, and a quick ratio of 9.27. The fifty day moving average price for MTNB is $0.1926 and a two-hundred day moving average price translates $0.3705 for the stock.

The latest earnings results from Matinas Biopharma Holdings Inc (AMEX: MTNB) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.03, inline with analysts’ expectations of -$0.03. This compares to -$0.03 EPS in the same period last year. The net profit margin was -641.60% and return on equity was -58.47% for MTNB.

Matinas Biopharma Holdings Inc(MTNB) Company Profile

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead’s antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

Related Posts